Stress Urinary Incontinence (SUI)
Versameb’s lead molecule is currently undergoing advanced preclinical development activities for the treatment of stress urinary incontinence. A significant acceleration of functional recovery and tissue regeneration has been observed after different types of injuries in preclinical models, showing its regenerative potential.
With the lead molecule moving towards clinic and the advance of additional assets in therapeutic areas of high unmet medical need, Versameb is creating an attractive and balanced portfolio.
Between 15% and 50% of adult women worldwide suffer from SUI. There is currently no drug treatment approved that restores function and has a long-term effect. This is a hard to treat disease where we expect Versameb technology to allow rejuvenation of the urinary sphincter.
For more information and resources on stress urinary incontinence, please see our SUI fact sheet (PDF, 506KB).